# NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology.

- URL: https://theranews.net/blog/2026-06-06-nrx-pharmaceuticals-nasdaqnrxp-notes-presentation-by-osmind-inc-of-iv-ketamine-e-7a60d5/
- Published: 2026-06-06
- Type: Archive summary (AI-assisted summary of third-party reporting)
- Original outlet: benzinga
- Original report: https://www.benzinga.com/pressreleases/26/06/g53025186/nrx-pharmaceuticals-nasdaq-nrxp-notes-presentation-by-osmind-inc-of-iv-ketamine-efficacy-vs-nasal-
- Topics: depression
- Publisher: TheraNews, operated by AdvancedCare USA Inc.
- Notice: Educational content, not medical, legal, billing or financial advice. Cite the original outlet, not this summary.

> Osmind presented a retrospective comparative study of de-identified electronic health record data in a sample of 8,224 patients with treatment resistant depression treated with IV ketamine and 1,830 patients treated with intranasal esketamine from 800 community psychiatry clinics. IV ketamine patien

---
![NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology.](/uploads/news-images/nrx-pharmaceuticals-nasdaq-nrxp-notes-presentati-20260606170041.png)

---
*Originally reported by benzinga. [Read more](https://www.benzinga.com/pressreleases/26/06/g53025186/nrx-pharmaceuticals-nasdaq-nrxp-notes-presentation-by-osmind-inc-of-iv-ketamine-efficacy-vs-nasal-)*

---

*Source: [https://www.benzinga.com/pressreleases/26/06/g53025186/nrx-pharmaceuticals-nasdaq-nrxp-notes-presentation-by-osmind-inc-of-iv-ketamine-efficacy-vs-nasal-](https://www.benzinga.com/pressreleases/26/06/g53025186/nrx-pharmaceuticals-nasdaq-nrxp-notes-presentation-by-osmind-inc-of-iv-ketamine-efficacy-vs-nasal-)*